Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Nyxoah S.A.NASDAQ: NYXH

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of €2.22M rose 237.5% year over year, ahead of the +175.8% change in trailing-twelve-month gross profit. Sequentially, it fell 38.7% from the prior quarter. Over 3 fiscal years it compounded at +48.4% a year.

Context

  • Gross profit amounted to 63.1% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +237.5% holds above the trailing-twelve-month pace of +175.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€2.22M-38.7% QoQ
Last fiscal yearDec 2025
€6.33M+113.1% YoY
LTMMar 2026
€7.89M+175.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+237.5%——
1 year+113.1%——
3-year CAGR+48.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
6.33M EUR
Year-over-year change
+113.1%
4-year CAGR
+84.2%

Gross Profit vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +175.8% is the 2nd highest of 9, against a peer median of +5.7%.
  • Gross profit amounts to 48.3% of revenue for NYXH, versus a peer median of 56.0%.
NYXH Competitors
Gross Profit for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$72.72M USD+28.0%+13.3%48.0%
PREPrenetics Global LimitedLTM Mar 2026$66.34M USD+249.9%+138.0%58.3%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.35M USD-32.6%-31.3%41.0%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$26.59M USD+19.4%+18.5%61.5%
UTMDUtah Medical Products, Inc.LTM Mar 2026$20.13M USD-8.0%-14.9%53.6%
OABIOmniAb, Inc.LTM Mar 2026$10.25M USD-61.7%—35.5%
NYXHNyxoah S.A.LTM Mar 2026€7.89M EUR+175.8%+48.4%48.3%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$90K USD———
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$3.03M USD-150.0%—489.8%
Peer median (excluding NYXH) —+5.7%+13.3%56.0%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.